Wolfgang Siess

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7515251/wolfgang-siess-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

6,302 41 135 75 h-index g-index citations papers 6,682 5.66 143 7.1 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
135	VITT after ChAdOx1 nCoV-19 Vaccination. <i>New England Journal of Medicine</i> , 2021 , 385, 2202-2203	59.2	1
134	Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. <i>Cancers</i> , 2021 , 13,	6.6	16
133	Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1395-1399	7	34
132	Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and Bleeding Time. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 749022	5.4	1
131	Glycoprotein VI is not a Functional Platelet Receptor for Fibrin Formed in Plasma or Blood. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 977-993	7	5
130	Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors. <i>Platelets</i> , 2020 , 31, 989-992	3.6	4
129	Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 397-4	o 7 6	21
128	Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1212-1221	7	21
127	Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcRIIA): a new option in HIT?. <i>Blood Advances</i> , 2019 , 3, 4021-4033	7.8	20
126	Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 351-361	7	19
125	Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. <i>Blood</i> , 2018 , 131, 2605-2616	2.2	52
124	ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions. Journal of the American Heart Association, 2017 , 6,	6	14
123	Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1651-1659	7	12
122	Platelet receptors as therapeutic targets: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1249-1257	7	42
121	Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaqueand Collagen-Induced Platelet Activation. <i>JACC Basic To Translational Science</i> , 2016 , 1, 131-142.	8.7	8
120	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. <i>Science Translational Medicine</i> , 2016 , 8, 367ra168	17.5	27
119	Cathepsin G Controls Arterial But Not Venular Myeloid Cell Recruitment. <i>Circulation</i> , 2016 , 134, 1176-17	1 86 .7	40

(2010-2015)

118	Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2015 , 36, 3202-10	9.5	59
117	Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2404-15	15.1	33
116	Activation of platelets by the endocannabinoids 2-arachidonoylglycerol and virodhamine is mediated by their conversion to arachidonic acid and thromboxane A2, not by activation of cannabinoid receptors. <i>Platelets</i> , 2014 , 25, 465-6	3.6	5
115	Inflammatory role and prognostic value of platelet chemokines in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 1277-87	7	32
114	Mechanism of platelet activation induced by endocannabinoids in blood and plasma. <i>Platelets</i> , 2014 , 25, 151-61	3.6	25
113	Stereo specific platelet inhibition by the natural LXR agonist 22(R)-OH-cholesterol and its fluorescence labelling with preserved bioactivity and chiral handling in macrophages. <i>Biochemical Pharmacology</i> , 2013 , 86, 279-85	6	8
112	I integrin-mediated signals are required for platelet granule secretion and hemostasis in mouse. <i>Blood</i> , 2013 , 122, 2723-31	2.2	20
111	Cofilin oligomer formation occurs in vivo and is regulated by cofilin phosphorylation. <i>PLoS ONE</i> , 2013 , 8, e71769	3.7	17
110	Lysophosphatidic acid in atherosclerotic diseases. British Journal of Pharmacology, 2012, 167, 465-82	8.6	69
109	Why and how to eliminate spontaneous platelet aggregation in blood measured by multiple electrode aggregometry. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1710-4	15.4	14
108	Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells. <i>PLoS ONE</i> , 2012 , 7, e33963	3.7	9
107	Effect of 5-HT2A receptor antagonists on human platelet activation in blood exposed to physiologic stimuli and atherosclerotic plaque. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 2112-5	15.4	13
106	The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 158-66	5.1	29
105	GPR92/LPAIlysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques. <i>Cardiovascular Research</i> , 2011 , 90, 157-64	9.9	24
104	STK35L1 associates with nuclear actin and regulates cell cycle and migration of endothelial cells. <i>PLoS ONE</i> , 2011 , 6, e16249	3.7	24
103	Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 1272-4	7	6
102	The EP3-agonist sulprostone, but not prostaglandin E2 potentiates platelet aggregation in human blood. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 1268-9	7	9
101	A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1147-58	15.1	133

100	Rac1-mediated signaling plays a central role in secretion-dependent platelet aggregation in human blood stimulated by atherosclerotic plaque. <i>Journal of Translational Medicine</i> , 2010 , 8, 128	8.5	28
99	Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. <i>Thrombosis Journal</i> , 2010 , 8, 9	5.6	19
98	Identifying and characterizing a novel protein kinase STK35L1 and deciphering its orthologs and close-homologs in vertebrates. <i>PLoS ONE</i> , 2009 , 4, e6981	3.7	6
97	Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. <i>Journal of Biological Chemistry</i> , 2009 , 284, 17304-17319	5.4	110
96	Unraveling a novel Rac1-mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin-stimulated platelets. <i>Blood</i> , 2009 , 114, 415-24	2.2	45
95	FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 370, 603-8	3.4	14
94	Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin. <i>Platelets</i> , 2008 , 19, 415-27	3.6	37
93	Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. <i>Basic Research in Cardiology</i> , 2008 , 103, 356-67	11.8	79
92	D-Glucose-recognition and phlorizin-binding sites in human sodium/D-glucose cotransporter 1 (hSGLT1): a tryptophan scanning study. <i>Biochemistry</i> , 2007 , 46, 13616-28	3.2	30
91	Sodium-independent low-affinity D-glucose transport by human sodium/D-glucose cotransporter 1: critical role of tryptophan 561. <i>Biochemistry</i> , 2007 , 46, 2758-66	3.2	10
90	Glycoprotein Iblinhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 435-443	7	45
89	Lysophosphatidic acid stimulation of platelets rapidly induces Ca2+-dependent dephosphorylation of cofilin that is independent of dense granule secretion and aggregation. <i>Blood Cells, Molecules, and Diseases,</i> 2007 , 38, 269-79	2.1	19
88	Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006 , 35, 292-304		31
87	Phosphorylation-dependent regulation of unique nuclear and nucleolar localization signals of LIM kinase 2 in endothelial cells. <i>Journal of Biological Chemistry</i> , 2006 , 281, 25223-30	5.4	29
86	Regulation of LIM-kinase 1 and cofilin in thrombin-stimulated platelets. <i>Blood</i> , 2006 , 107, 575-83	2.2	44
85	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 4919-30	8.3	92
84	High-yield functional expression of human sodium/d-glucose cotransporter1 in Pichia pastoris and characterization of ligand-induced conformational changes as studied by tryptophan fluorescence. <i>Biochemistry</i> , 2005 , 44, 15514-24	3.2	28
83	Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2005 , 25, 546-52	9.4	76

(1999-2005)

82	Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. <i>FASEB Journal</i> , 2005 , 19, 898-909	0.9	120
81	Inhibition of nuclear import of LIMK2 in endothelial cells by protein kinase C-dependent phosphorylation at Ser-283. <i>Journal of Biological Chemistry</i> , 2005 , 280, 27569-77	5.4	21
80	Structural identification of oxidized acyl-phosphatidylcholines that induce platelet activation. Journal of Vascular Research, 2005 , 42, 120-32	1.9	26
79	Thrombogenic and atherogenic activities of lysophosphatidic acid. <i>Journal of Cellular Biochemistry</i> , 2004 , 92, 1086-94	4.7	96
78	The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. <i>Blood</i> , 2004 , 103, 2585	- 32	95
77	Does cGMP mediate platelet inhibition or stimulation?. <i>Blood</i> , 2004 , 103, 2435-2436	2.2	
76	Human Atheromatous Plaques Stimulate Thrombus Formation by Activating Platelet Glycoprotein VI <i>Blood</i> , 2004 , 104, 2623-2623	2.2	
75	Cross-talk of cGMP- and cAMP-signaling pathways in human platelets. <i>Blood</i> , 2003 , 101, 4230-4230	2.2	
74	Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. <i>Cellular Signalling</i> , 2003 , 15, 367-75	4.9	77
73	Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. <i>Circulation</i> , 2003 , 108, 741-7	16.7	132
7 ²	Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2002 , 1582, 204-15	5	124
71	Phosphatidylinositol 3-kinase-dependent translocation of phospholipase Cgamma2 in mouse megakaryocytes is independent of Bruton tyrosine kinase translocation. <i>Blood</i> , 2001 , 97, 678-84	2.2	42
70	Sphingosine-1-Phosphate and the Leading Edg-1 of Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 2001 , 89, 474-476	15.7	2
69	Stimulation of platelets and endothelial cells by mildly oxidized LDL proceeds through activation of lysophosphatidic acid receptors and the Rho/Rho-kinase pathway. Inhibition by lovastatin. <i>Annals of the New York Academy of Sciences</i> , 2000 , 905, 282-6	6.5	26
68	Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. <i>Journal of Biological Chemistry</i> , 2000 , 275, 19159-66	5.4	61
67	Mildly oxidised low density lipoprotein induces platelet shape change via Rho-kinase-dependent phosphorylation of myosin light chain and moesin. <i>FEBS Letters</i> , 2000 , 466, 70-4	3.8	28
66	ADP-induced platelet shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation. <i>Platelets</i> , 2000 , 11, 286-95	3.6	49
65	Increased adhesion and aggregation of platelets lacking cyclic guanosine 3Ţ5Ŧmonophosphate kinase I. <i>Journal of Experimental Medicine</i> , 1999 , 189, 1255-64	16.6	195

64	Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. <i>Journal of Biological Chemistry</i> , 1999 , 274, 30361-4	5.4	102
63	Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 6931-6	11.5	354
62	Platelet agonists enhance the import of phosphatidylethanolamine into human platelets. <i>Journal of Biological Chemistry</i> , 1998 , 273, 27800-8	5.4	16
61	Dissociation of the alphallbbeta3-integrin by EGTA stimulates the tyrosine kinase pp72(syk) without inducing platelet activation. <i>Journal of Biological Chemistry</i> , 1996 , 271, 26547-53	5.4	12
60	Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost. <i>European Journal of Pharmacology</i> , 1995 , 288, 329-33		12
59	Thrombin receptor-activating peptide sensitizes the human endothelial thrombin receptor. <i>American Journal of Physiology - Cell Physiology</i> , 1995 , 268, C36-44	5.4	9
58	Platelet shape change induced by thrombin receptor activation. Rapid stimulation of tyrosine phosphorylation of novel protein substrates through an integrin- and Ca(2+)-independent mechanism. <i>Journal of Biological Chemistry</i> , 1995 , 270, 1057-61	5.4	54
57	The Thrombostat system. A useful method to test antiplatelet drugs and diets. <i>Seminars in Thrombosis and Hemostasis</i> , 1995 , 21 Suppl 2, 25-31	5.3	9
56	Integrin alpha IIb beta 3-mediated translocation of CDC42Hs to the cytoskeleton in stimulated human platelets. <i>Journal of Biological Chemistry</i> , 1995 , 270, 17321-6	5.4	47
55	The association of pp125FAK, pp60Src, CDC42Hs and Rap1B with the cytoskeleton of aggregated platelets is a reversible process regulated by calcium. <i>FEBS Letters</i> , 1995 , 363, 231-4	3.8	27
54	Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. <i>Cardiovascular Drugs and Therapy</i> , 1995 , 9, 619-29	3.9	15
53	Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators. <i>Journal of Cardiovascular Pharmacology</i> , 1995 , 25, 545-51	3.1	14
52	Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 1995 , 15, 1131-8	9.4	90
51	Formation of biologically active autacoids is regulated by calcium influx in endothelial cells. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology,</i> 1994 , 14, 1821-8		24
50	Lovastatin inhibits receptor-stimulated Ca(2+)-influx in retinoic acid differentiated U937 and HL-60 cells. <i>Cellular Signalling</i> , 1994 , 6, 735-42	4.9	13
49	Integrin-dependent protein dephosphorylation on tyrosine induced by activation of the thrombin receptor in human platelets. <i>Cellular Signalling</i> , 1994 , 6, 279-84	4.9	13
48	Thrombin-induced Ca2+ influx and protein tyrosine phosphorylation in endothelial cells is inhibited by herbimycin A. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 202, 1651-6	3.4	29
47	Simple method of RNA isolation from human leucocytic cell lines. <i>Nucleic Acids Research</i> , 1993 , 21, 4852	2- 3 0.1	7

46	Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. <i>Immunopharmacology</i> , 1993 , 26, 259-64		88
45	Activation of the cloned platelet thrombin receptor decreases the pertussis-toxin-dependent ADP-ribosylation of the membrane and soluble inhibitory guanine-nucleotide-binding-alpha proteins. Inhibition by the prostacyclin analog, iloprost. <i>FEBS Journal</i> , 1993 , 216, 81-8		5
44	Phosphorylation of rap1B by protein kinase A is not involved in platelet inhibition by cyclic AMP. <i>Cellular Signalling</i> , 1993 , 5, 209-14	4.9	17
43	Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition. <i>Advances in Experimental Medicine and Biology</i> , 1993 , 344, 229-35	3.6	12
42	Thrombin inhibits the pertussis-toxin-dependent ADP-ribosylation of a novel soluble Gi-protein in human platelets. <i>Biochemical Journal</i> , 1991 , 279 (Pt 3), 643-50	3.8	13
41	Ca2+ ionophore A23187 and thrombin inhibit the pertussis-toxin-induced ADP-ribosylation of the alpha-subunit of the inhibitory guanine-nucleotide-binding protein and other proteins in human platelets. <i>FEBS Journal</i> , 1991 , 202, 145-50		7
40	Multiple Signal-Transduction Pathways Synergize in Platelet Activation. <i>Physiology</i> , 1991 , 6, 51-56	9.8	2
39	Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition. <i>Biochemical Journal</i> , 1990 , 271, 815-9	3.8	57
38	Rap1-B is phosphorylated by protein kinase A in intact human platelets. <i>Biochemical and Biophysical Research Communications</i> , 1990 , 170, 944-50	3.4	87
37	Platelets in the pathogenesis of atherosclerosis. <i>Advances in Experimental Medicine and Biology</i> , 1990 , 273, 119-27	3.6	4
36	Epinephrine potentiates calcium mobilization and activation of protein kinases in platelets stimulated by ADP through a mechanism unrelated to phospholipase C. <i>Cellular Signalling</i> , 1989 , 1, 483-	. 92 9	29
35	Epinephrine and the Ca2+ ionophore A23187 synergistically induce platelet aggregation without protein kinase C activation. <i>FEBS Letters</i> , 1989 , 243, 275-9	3.8	9
34	Prostacyclin inhibits platelet aggregation induced by phorbol ester or Ca2+ ionophore at steps distal to activation of protein kinase C and Ca2+-dependent protein kinases. <i>Biochemical Journal</i> , 1989 , 258, 57-65	3.8	42
33	Platelet aggregation induced by alpha 2-adrenoceptor and protein kinase C activation. A novel synergism. <i>Biochemical Journal</i> , 1989 , 263, 377-85	3.8	47
32	Molecular mechanisms of platelet activation. <i>Physiological Reviews</i> , 1989 , 69, 58-178	47.9	801
31	Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity. <i>Thrombosis Research</i> , 1988 , 52, 11-21	8.2	90
30	Measurement of inositol phospholipid turnover in platelets. <i>Methods in Enzymology</i> , 1987 , 141, 176-92	1.7	33
29	Activation of V1-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets. <i>Biochemical Journal</i> , 1986 , 233, 83-91	3.8	96

Phosphoinositides and prostaglandins in regulation of platelet function. Fresenius Zeitschrift Flandlytische Chemie, 1986, 324, 238-239

27	High-performance liquid chromatography la suitable method to separate inositol phosphates and glycerophosphoinositol phosphates. <i>Fresenius Zeitschrift Fl Analytische Chemie</i> , 1986 , 324, 341-342		
26	Neomycin inhibits inositol phosphate formation in human platelets stimulated by thrombin but not other agonists. <i>FEBS Letters</i> , 1986 , 207, 53-7	3.8	39
25	Inositol phospholipid metabolism and platelet function. <i>Biochemical Pharmacology</i> , 1986 , 35, 3184-7	6	16
24	Separation of inositol phosphates and glycerophosphoinositol phosphates by high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 1985 , 148, 220-7	3.1	50
23	Thrombin induces the rapid formation of inositol bisphosphate and inositol trisphosphate in human platelets. <i>FEBS Letters</i> , 1985 , 180, 107-12	3.8	19
22	Evidence for the formation of inositol 4-monophosphate in stimulated human platelets. <i>FEBS Letters</i> , 1985 , 185, 151-6	3.8	38
21	Uptake, release and metabolism of docosahexaenoic acid (DHA, c22:6 omega 3) in human platelets and neutrophils. <i>Biochemical and Biophysical Research Communications</i> , 1984 , 120, 907-18	3.4	115
20	Dihomogammalinolenic acid, but not eicosapentaenoic acid, activates washed human platelets. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1984 , 801, 265-76	4	15
19	Prostaglandins and hypertension. Advances in Experimental Medicine and Biology, 1984 , 164, 269-81	3.6	1
18	The role of phospholipase C in platelet responses. <i>Life Sciences</i> , 1983 , 33, 1011-8	6.8	70
17	Properties and distribution of phosphatidylinositol-specific phospholipase C in human and horse platelets. <i>Lipids and Lipid Metabolism</i> , 1983 , 752, 329-38		61
16	Effects of propranolol in vitro and in vivo on platelet function and thromboxane formation in normal volunteers. <i>Agents and Actions</i> , 1983 , 13, 29-34		9
15	Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. <i>Circulation</i> , 1982 , 66, 44-8	16.7	136
14	Cytochalasins inhibit arachidonic acid metabolism in thrombin-stimulated platelets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1982 , 79, 7709-13	11.5	19
13	Analysis of 6-keto-prostaglandin F1 alpha in human urine: age-specific differences. <i>Prostaglandins</i> , 1982 , 23, 41-52		22
12	In vitro prostaglandin synthesis by various rat renal preparations. <i>Lipids and Lipid Metabolism</i> , 1982 , 710, 45-52		41
11	Arachidonic acid metabolites, hypertension and arteriosclerosis. Klinische Wochenschrift, 1982 , 60, 479	-88	13

LIST OF PUBLICATIONS

10	Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man. <i>European Journal of Pharmacology</i> , 1981 , 70, 511-8	5 ·3	26
9	Aggregation and thromboxane B2 formation in platelets and vascular prostacyclin production from genetically obese rats. <i>Prostaglandins</i> , 1981 , 22, 521-36		14
8	Interactions of renal prostaglandins with the renin-angiotensin system 1981 , 15, 321-37		12
7	Prostanoid synthesis by vascular slices and cultured vascular cells of piglet aorta. <i>Biochemical and Biophysical Research Communications</i> , 1981 , 99, 608-16	3.4	19
6	Dissociation of platelet activation from transmethylation of their membrane phospholipids. <i>Nature</i> , 1981 , 293, 660-2	50.4	31
5	Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. <i>Lancet, The</i> , 1980 , 1, 441-4	40	429
4	Possible significance of renal prostaglandins in essential hypertension. <i>Clinical and Experimental Hypertension</i> , 1980 , 2, 741-60		11
3	Formation and action of prostaglandins in the kidney. Klinische Wochenschrift, 1979 , 57, 1021-9		27
2	Urinary prostaglandins and kallikrein in essential hypertension. <i>Clinical Science</i> , 1979 , 57 Suppl 5, 259s-26	51s	31
1	Radioimmunological and biological measurement of prostaglandins in rabbit urine: decrease of PGE2 excretion at high NaCl intake. <i>Prostaglandins</i> , 1977 , 13, 1127-39		33